Periodontics and Prosthodontics Open Access

  • ISSN: 2471-3082
  • Journal h-index: 6
  • Journal CiteScore: 0.87
  • Journal Impact Factor: 0.57
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days


Dehydrated Human Amnion-Chorion Product as an Adjunct to Scaling and Root Planing in Maintenance Patients: A Pilot Study

John R. Dodge ,Anthony C. Rademacher

Background: Adjunctive therapies are often combined with Scaling and Root Planing (SRP) procedures to limit bacterial recolonization of periodontal pockets and to modulate the wound healing environment. While local delivery antimicrobial therapies are effective, they do not promote soft tissue repair at these sites. BioXclude, a dehydrated human de-epithelialized amnion-chorion membrane product (ddACM) sourced from donated human placental tissue, has been shown to have antimicrobial properties, contain stimulatory growth factors known to activate wound healing processes, and possess critical attachment substrates for cellular adhesion and migration. Given this combination, it was hypothesized that ddACM would be an effective adjunctive therapy for the treatment of periodontal pockets following SRP procedures.

Methods: Sixteen non-smoking patients, compliant with a regular periodontal maintenance program, were included in this study. A total of 30 sites showing a ≥ 2 mm increase in periodontal probing depth (PPD), with associated bleeding on probing (BOP), were chosen for treatment. Following standard SRP procedures with local anesthesia, ddACM was placed into the treated area. A six-week periodontal re-evaluation was completed, with the primary outcome variable being PD reduction and secondary outcomes that included resolution of bleeding on probing (BOP).

Results: Mean PD reduction was 2.55 mm ± 0.34 mm, with three sites showing ≥ 4 mm ± 0.2 mm reduction in PD. BOP was resolved in 83% of the treated sites.

Conclusion: ddACM provides significant benefit as an adjunctive therapy to SRP for the treatment of periodontal pockets in terms of PD reduction and resolution of BOP.